ORIGINAL ARTICLE
Increased Glypican-3 immunostaining is associated with longer survival outcomes in colorectal carcinoma
1
Department of Pathology, King Abdulaziz University, Jeddah, Saudi Arabia
2
Department of Pathology, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
3
Department of Pathology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia
4
Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
5
Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
6
Department of Pathology, Faculty of Medicine, Minia University, Al Minia, Egypt
Submission date: 2021-10-09
Final revision date: 2022-02-22
Acceptance date: 2022-03-14
Publication date: 2022-06-28
Pol J Pathol 2022;73(1):14-20
KEYWORDS
TOPICS
ABSTRACT
Glypicans (GPC) are involved in the developmental morphogenesis and regulatory processes of cell signalling. Abnormal expression has been observed in different cancer types.
One hundred and thirty-seven colorectal carcinoma (CRC) and 44 nodal metastases were used to create tissue microarrays. Immunohistochemistry was done to detect and evaluate the impact of immunostaining patterns of GPC-3 protein in CRC.
GPC-3 immunostaining is increased in CRC and nodal metastasis (p < 0.001) and was not association with clinicopathological parameters. GPC-3 immunostaining was associated with longer disease-free survival (p = 0.021) and overall survival (p = 0.05).
For the first time, we show GPC-3 immunostaining association with survival outcomes in CRC. GPC-3 may be used as an independent prognostic factor for survival in CRC.
One hundred and thirty-seven colorectal carcinoma (CRC) and 44 nodal metastases were used to create tissue microarrays. Immunohistochemistry was done to detect and evaluate the impact of immunostaining patterns of GPC-3 protein in CRC.
GPC-3 immunostaining is increased in CRC and nodal metastasis (p < 0.001) and was not association with clinicopathological parameters. GPC-3 immunostaining was associated with longer disease-free survival (p = 0.021) and overall survival (p = 0.05).
For the first time, we show GPC-3 immunostaining association with survival outcomes in CRC. GPC-3 may be used as an independent prognostic factor for survival in CRC.
REFERENCES (39)
2.
Fearon ER, Carethers JM. Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome. Gastroenterology 2015; 148: 10-13.
3.
Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507.
4.
Serafino A, Moroni N, Zonfrillo M, et al. WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer. Oncotarget 2014; 5: 978-992.
5.
Lin X. Functions of heparan sulfate proteoglycans in cell signaling during development. Development 2004; 131: 6009-6021.
6.
Franch-Marro X, Marchand O, et al. Glypicans shunt the Wingless signal between local signalling and further transport. Development 2005; 132: 659-666.
7.
Capurro MI, Xu P, Shi W, et al. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell 2008; 14: 700-711.
8.
Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling. Cancer Res 2005; 65: 6245.
9.
Baumhoer D, Tornillo L, Stadlmann S, et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 2008; 129: 899-906.
10.
Montalbano M, Georgiadis J, Masterson AL, et al. Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma (Review). Oncol Rep 2017; 37: 1291-1300.
11.
Capurro M, Filmus J. Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res 2005; 65: 372.
12.
Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005; 65: 6245-6254.
13.
Chan ES, Pawel BR, Corao DA, et al. Immunohistochemical expression of glypican-3 in pediatric tumors: an analysis of 414 cases. Pediatr Dev Pathol 2013; 16: 272-277.
14.
Ning S, Bin C, Na H, et al. Glypican-3, a novel prognostic marker of hepatocellular cancer, related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep 2012; 39: 351-357.
15.
Yuan DH, Xie HH, Wang Y, et al. [Expression and significance of glypican-3 in colorectal cancer]. Zhonghua Yi Xue Za Zhi 2008; 88: 1540-1542.
16.
Al-Maghrabi J, Gomaa W, Buhmeida A, et al. Prognostic significance of VEGFR1/Flt-1 immunoexpression in colorectal carcinoma. Tumour Biol 2014; 35: 9045-9051.
17.
Gomaa W, Ke Y, Fujii H, Helliwell T. Tissue microarray of head and neck squamous carcinoma: validation of the methodology for the study of cutaneous fatty acid-binding protein, vascular endothelial growth factor, involucrin and Ki-67. Virchows Arch 2005; 447: 701-709.
18.
Ou-Yang RJ, Hui P, Yang XJ, Zynger DL. Expression of glypican 3 in placental site trophoblastic tumor. Diagn Pathol 2010; 5: 64.
19.
Castillo LF, Tascón R, Lago Huvelle MA, et al. Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells. Oncotarget 2016; 7: 60133-60154.
20.
Fleming BD, Ho M. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins (Basel) 2016; 8: 274.
21.
Haruyama Y, Kataoka H. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol 2016; 22: 275-283.
22.
Liu H, Yang C, Lu W, Zeng Y. Prognostic significance of glypican-3 expression in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2018; 97: e9702.
23.
Zhang J, Zhang M, Ma H, et al. Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis. Medicine (Baltimore) 2018; 97: e11130.
24.
Aydin O, Yildiz L, Baris S, et al. Expression of Glypican 3 in low and high grade urothelial carcinomas. Diagn Pathol 2015; 10: 34.
25.
Maeda D, Ota S, Takazawa Y, et al. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol 2009; 22: 824-32.
26.
Hakim SA, Raboh NMA. Immunohistochemical expression of glypican 3 in endometrial carcinoma and correlation with prognostic parameters. Int J Clin Exp Pathol 2015; 8: 13225-13232.
27.
Yao H, Yang Z, Liu Z, et al. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. Cancer Biomark 2016; 174: 397-404.
28.
Azizpour S, Ezati R, Saidijam M, et al. The expression of glypican-3 in colorectal cancer. Cytology and Genetics 2019; 53: 430-440.
29.
Foda AA, Mohammad MA, Abdel-Aziz A, El-Hawary AK. Relation of glypican-3 and E-cadherin expressions to clinicopathological features and prognosis of mucinous and non-mucinous colorectal adenocarcinoma. Tumour Biol 2015; 36: 4671-4679.
30.
Joo EJ, Weyers A, Li G, et al. Carbohydrate-containing molecules as potential biomarkers in colon cancer. OMICS 2014; 18: 231-241.
31.
De Robertis M, Arigoni M, Loiacono L, et al. Novel insights into Notum and glypicans regulation in colorectal cancer. Oncotarget 2015; 6: 41237-41257.
32.
Marolla AP, Waisberg J, Saba GT, et al. Glycomics expression analysis of sulfated glycosaminoglycans of human colorectal cancer tissues and non-neoplastic mucosa by electrospray ionization mass spectrometry. Einstein (Sao Paulo). 2015;13(4):510-7.
33.
Moek KL, Fehrmann RSN, van der Vegt B, et al. Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database. Am J Pathol 2018; 188: 1973-1981.
34.
Luo W, Ren Z, Gao S, et al. Clinical correlation of calpain-1 and glypican-3 expression with gallbladder carcinoma. Oncol Lett 2016; 11: 1345-1352.
35.
Chen IP, Ariizumi S, Nakano M, Yamamoto M. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol 2014; 49: 117-125.
36.
Kim JY, Park DY, Kim GH, et al. Does clear cell carcinoma of stomach exist? Clinicopathological and prognostic significance of clear cell changes in gastric adenocarcinomas. Histopathology 2014; 65: 90-99.
37.
Morford LA, Davis C, Jin L, et al. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. Hepatology 2007; 46: 1541-1547.
38.
Li N, Gao W, Zhang Y-F, Ho M. Glypicans as Cancer Therapeutic Targets. Trends Cancer 2018; 4: 741-754.
39.
Shimizu Y, Suzuki T, Yoshikawa T, et al. Cancer immunotherapy-targeted glypican-3 or neoantigens. Cancer Sci 2018; 109: 531-541.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
